Osteomyelitis due to multiple carbapenemase-producing Gram-negative bacteria: The first case report of a GES-13-producing Pseudomonas aeruginosa isolate in Canada

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 25, Issue 4, 2014, Pages 229-231

  Sepehri, Shadi ^a   Poliquin, Guillaume ^a,b,c   Alfattoh, Nora ^b   Boyd, David ^c   Mulvey, Michael ^a,c   Denisuik, Andrew ^a   Fanella, Sergio ^a,b   Karlowsky, James ^a,d   Walkty, Andrew ^a,d  

^a HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d Diagnostic Services of Manitoba Inc   (Canada)

Author keywords

Carbapenemase; Continuous infusion; GES 13; Multidrugresistant; OXA 48

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; CEFAZOLIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; MEROPENEM; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ADD ON THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; BURN INFECTION; CANADA; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CASE REPORT; CONTINUOUS INFUSION; FEMALE; GES 13 PRODUCING PSEUDOMONAS AERUGINOSA; HUMAN; HUMAN TISSUE; INFANT; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; OSTEOMYELITIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; TREATMENT RESPONSE;

EID: 84910637421     PISSN: 17129532     EISSN: 19181493     Source Type: Journal    
DOI: 10.1155/2014/657047     Document Type: Article

References (17)

1. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement. M100-S23. Wayne: Clinical and Laboratory Standards Institute, 2013.
2. Mulvey MR, Chui L, Ismail J, et al. Development of a Canadian standardized protocol for subtyping methicillin-resistant Staphylococcus aureus using pulsed-field gel electrophoresis. J Clin Microbiol 2001;39: 3481-5.
3. Mataseje LF, Bryce E, Roscoe D, et al. Carbapenem-resistant Gramnegative bacilli in Canada 2009-10: Results from the Canadian Nosocomial Infection Surveillance Program (CNISP). J Antimicrob Chemother 2012;67: 1359-67.
4. Mataseje LF, Boyd DA, Hoang L, et al. Carbapenem-hydrolyzing oxacillinase-48 and oxacillinase-181 in Canada, 2011. Emerg Infect Dis 2013;19: 157-60.
5. Cornaglia G, Rossolini GM. The emerging threat of acquired carbapenemases in Gram-negative bacteria. Clin Microbiol Infect 2010;16: 99-101.
6. Kotsakis SD, Miriagou V, Tzelepi E, Tzouvelekis LS. Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. Antimicrob Agents Chemother 2010;54: 4864-71.
7. Kotsakis SD, Papagiannitsis CC, Tzelepi E, Legakis NJ, Miriagou V, Tzouvelekis LS. GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010;54: 1331-3.
8. Walther-Rasmussen J, Hoiby N. Oxa-Type carbapenemases. J Antimicrob Chemother 2006;57: 373-83.
9. Potron A, Poirel L, Rondinaud E, Nordmann P. Intercontinental spread of OXA-48 beta-lactamase-producing Enterobacteriaceae over a 11-year period, 2001 to 2011. Euro Surveill 2013;18: pii=20549.
10. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: The phantom menace. J Antimicrob Chemother 2012;67: 1597-606.
11. Kilic A, Aktas Z, Bedir O, et al. Identification and characterization of OXA-48 producing, carbapenem-resistant Enterobacteriaceae isolates in Turkey. Ann Clin Lab Sci 2011;41: 161-6.
12. Mathers AJ, Hazen KC, Carroll J, et al. First clinical cases of OXA-48-producing carbapenem-resistant Klebsiella pneumoniae in the United States: the "menace" arrives in the new world. J Clin Microbiol 2013;51: 680-3. (Erratum in 2013;51: 1352).
13. Nordmann P, Gniadkowski M, Giske CG, et al. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2012;18: 432-8.
14. Doyle D, Peirano G, Lascols C, Lloyd T, Church DL, Pitout JD. Laboratory detection of Enterobacteriaceae that produce carbapenemases. J Clin Microbiol 2012;50: 3877-80.
15. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-Term intravenous infusion of carpabenems and piperacillin/tazobactam: A systematic review and meta-Analysis. Clin Infect Dis 2013;56: 272-82.
16. Moriyama B, Henning SA, Childs R, et al. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann Pharmacother 2010;44: 929-35.
17. Walker MC, Lam WM, Manasco KB. Continuous and extended infusions of β-lactam antibiotics in the pediatric population. Ann Pharmacother 2012;46: 1537-46.